January 06, 2025 07:59 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bharatiya Janata Party releases first list of candidates for Delhi Assembly polls, fields Parvesh Sahib Singh Verma against Kejriwal | Firecracker unit explosion in Tamil Nadu's Virudhunagar kills 6 | Body of independent journalist, who went missing on Jan 1, found in a septic tank in Chhattisgarh | Delhi: 14-year-old student stabbed to death outside school after brawl with classmate | Rohit Sharma confirms he is not retiring amid speculations after skipping Sydney Test | India objects to China's 'new counties' announcement, says parts of these come under Ladakh | No cause for alarm over HMPV virus spread in China: Indian Health Agency | PM Modi gives a call for change in Delhi launching fierce attack on Arvind Kejriwal's AAP | Quran open to passage glorifying violence, bomb-making materials tracked in New Orleans attacker Shamshud-Din Jabbar's home | Jasprit Bumrah leads India in series decider after Rohit Sharma opts to rest in Sydney Test amid poor show with willow
Dr Reddys
Image: Pixabay

Dr Reddy’s Q3 net profit up 77 pc at Rs 1,247 cr

| @indiablooms | Jan 25, 2023, at 11:39 pm

Hyderabad: Generic Drug maker, Dr Reddy’s Laboratories’ on Wednesday reported a 77 per cent increase in consolidated net profit to Rs 1,247 crore in the third quarter ended December 2022 as against Rs 706 crore in the corresponding quarter in the previous year.

The total revenue from operations was up by 27 per cent to Rs 6,770 crore as against Rs 5,319.7 crore, in the corresponding quarter in 2021, Hyderabad-based pharmaceutical giant said in a release here.

For the first nine-months ended December, 2022, the Pharma’s net profit rose by 56 percent to Rs 3,548 crore while revenues increased by 14 per cent to Rs 18,291 crore.

Commenting on the results, Co-chairman and Managing Director, G V Prasad said “Our strong financial performance was supported by growth in the US and the Russia markets.

He said we continue to strengthen our development pipeline to reach more patients globally.”

(With UNI inputs)

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.